acid-(Quercetin-C), common in berries, red fruits and nuts significantly fewer side effects and gives significantly better response when additional given chemotherapy for prostate cancer patients relapse of hormone resistant phase III study shows. Article update 30 May 2011

May 30, 2011: I'm reviewing cancer-news and came across this study on effect of ellagic acid with hormone resistant prostate cancer against. With beautiful therapeutic results. I've added the full study report at the bottom of a 2009 study of the effect of the pomegranate for prostate cancer. Scientists assume that the ellagic acid from pomegranate is responsible for the positive impact. Scroll to the bottom of the study report.

29 april 2005: source: Eur Urol. 2005 Apr; 47 (4): 449-54;

Although prostate cancerrarely chemo is given, only if all other treatments have lost their force, randomized phase III study shows that when given additional chemotherapy in addition to ellagic acid is at hormone resistant prostate cancer patients estramustine phosphate vinorelbine and the general response, so catch on significantly greater than when treatment is given, and also the only chemo side effects, including nerve pains, and quality of life are significantly better than the ellegic acid with additional chemo only. On the ultimate survival was no significant difference found, although also here an improvement for the ellagic acid group was found but not significant. Read yet another article about ellagic acid once where dozens of studies listed on favorable operation of ellegagic acid with many different types of cancer, including ovarian cancer and bladder cancer and breast cancer.You can of course ask ourselves whether there is no study should be done only with Ellagic Acid in addition to bv. hormone therapy in prostate cancer patients or maybe even better than the results.

Eur Urol. 2005 Apr; 47 (4): 449-54;

Ellagic acid therapy in patients with hormone refractory Support prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.

M, Tartarone A, Falsaperla Morgia G, Ardito R, Romano g., Centro di Riferimento Oncologico Operative Unit of Urology della Basilicata, Rionero in Vulture, Potenza, Italy. mayurol@yahoo.it BACKGROUND: Recent phase III studies in hormone refractory prostate cancer (HRPC) showed an improvement in terms of overall survival (OS), objective response (OR) and biochemical response (BR); however, chemotherapy is usually accompanied by negative side effects that poor quality of life (QoL) determines and only marginally improves individual clinical response (ICR) in terms of pain relief and performance status. Ellagic acid is a poly phenol that is found in many species of flowering plants. It is an antioxidant that determines apoptosis, down regulation of IGF-II, activates p21 (waf1/Cip1), mediates the cumulative effect on G1/S transition phase and prevents destruction of p-53 gene by cancer cells.

ENDPOINTS: The aim of this study was to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR inEstramustine phosphate and HRPC patients treated with vinorelbine.

MATERIALS AND METHODS: Patients with HRPC were randomly distributed in two study groups: a control group (group A) who underwent chemotherapy with vinorelbine and estramustine phosphate, and an experimental group (group B) where chemotherapy regimen was associated with ellagic acid.

RESULTS: The mean number of chemotherapy cycles/patient was 4 (range 3-8 cycles) and 6.5 (range 5-11) in group A and B patients, respectively. A reduction in systemic toxicity, statistically significant for neutropenia, associated with better results in term of OR rate, ICR, and BR were observed in group B compared with group a. On the contrary no significant difference in OS and PFS was detected between groups.

CONCLUSIONS: our study suggests that the use of ellagic acid as support therapy reduces chemotherapy induced toxicity, in het bijzonder neutropenia, in patients HRCP; however, further studies are required to confirm our results.

PMID: 15774240 [PubMed-in process]

Cancer Chemo prevention by Pomegranate: Laboratory and Clinical Evidence

Vaqar Adhami, Naghma Khan, and Hasan Mukhtar Mustafa
Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA
Address correspondence to Hasan Mukhtar, Helfaer Professor of Cancer Research, Director and Vice Chair for Research, Department of Dermatology, University of Wisconsin, 1300 University Avenue, Medical Sciences Center, Room B-25, Madison, WI 53706. Phone: 608-263-3927. Fax: 608-263-5223. hmukhtar@wisc.edu
Abstract
Pomegranate fruit from the tree Punica granatum has been dubbed as the "nature's power fruit." Dating back to Biblical times, the tree itself is attributed to possess extraordinary medicinal properties. The geographical distribution of the tree, being native to the Middle East and some Asian countries, is generally attributed to a lack of interest in its medicinal properties by many western scientists. However, the unique biochemical composition of the pomegranate fruit being rich in antioxidant flavonoids and tannins has recently drawn attention of many investigators to study its exceptional healing qualities. Recent research has shown that pomegranate extracts selectively inhibit the growth of breast, prostate, colon and lung cancer cells in culture. In preclinical animal studies, oral consumption of pomegranate extract inhibited growth of lung, skin, colon and prostate tumors. An initial phase II clinical trial of pomegranate juice in patients with prostate cancer or prostate specific antigen doubling time reported significant prolongation. This review focuses on recent investigations into the effects of pomegranate fruit on cancer.
INTRODUCTION
The fruit of the tree Punica granatum, grown mainly in the Mediterranean region, has been shown to possess many medicinal properties such as being antioxidant and anti-inflammatory (1). The antioxidant activity of flavonoids obtained from pomegranate juice (PJ) was observed to be close to that of butylated hydroxyanisole, green tea, and significantly greater than red wine (2,3). Commercially available pomegranate juices tested for their antioxidant Trolox Equivalent Antioxidant activity by the Capacity (TEAC) assay showed antioxidant activity or ~ 18 to 20 was three times higher than those of TEAC that red wine and green tea (6–8 TEAC). Interestingly, the antioxidant activity was higher in commercial juices that were extracted from whole pomegranates than in experimental juices that were obtained from the arils only (4). Antioxidant activities of freeze-dried preparations of pomegranate and its 3 major anthocyanidins (delphinidin, cyanidin, and pelargonidin) were evaluated by Noda et al. (3) by the method of electron spin resonance technique and spin trapping. Pomegranate extract exhibited scavenging activity against OH and equation M1 . The anthocyanidins were found to inhibit a Fenton reagent −OH generating system possibly by chelating with ferrous ion. Also, equation M2 in a dose-dependent anthocyanidins manner scavenged, and delphinidin, cyanidin ID values of50 , and pelargonidin were 2.4, 22,
and 456 µ M, respectively. Anthocyanidins inhibited H2O2-induced in the rat brain homogenates and lipid peroxidation ID delphinidin, cyanidin, values of50 and 85, 3.5, and pelargonidin were 0.7 µ M, respectively (3). Pomegranates have only recently been studied for their anticancer effects (Table 1). The following sections will summarize the studies on the effects of pomegranate against various cancers.
Read more >>>>>>>>